Cabaletta Bio, Inc. (CABA)

11,01 -1,17 (-9,61%) Alla chiusura: 04:00PM EDT

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
https://www.cabalettabio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 101

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Steven A. Nichtberger M.D.	Co-Founder, Chairman, CEO & President	970,6k	N/D	1961
Dr. Gwendolyn K. Binder Ph.D.	President of Science & Technology	692,99k	N/D	1975
Dr. David J. Chang FACR, M.D., M.P.H.	Chief Medical Officer	676,74k	N/D	1963
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/D	N/D	N/D
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/D	N/D	N/D
Mr. Anup Marda M.B.A.	Chief Financial Officer	548,2k	N/D	1978
Dr. Samik Basu M.D.	Chief Scientific Officer	N/D	N/D	N/D
Mr. Michael Gerard J.D.	General Counsel & Secretary	N/D	N/D	1980
Ms. Heather Harte-Hall M.Sc.	Chief Compliance Officer	N/D	N/D	N/D
Ms. Martha O'Connor	Chief Human Resources Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Cabaletta Bio, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 10; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.